Abstract: Described herein are polynucleotide constructs for inducible production of rAAV virions. Also provided are stable cell lines for inducible expression of rAAV virions that include a pay load poly nucleotide.

Abstract: Disclosed herein are engineered RNAs and compositions comprising the same for treatment of diseases or conditions in a subject. Also disclosed herein are methods of treating diseases or conditions in a subject by administering engineered RNAs, polynucleotides encoding the described engineered RNAs, or pharmaceutical compositions described here.

Abstract: Disclosed herein are engineered latent guide RNAs targeting LRRK2 and compositions comprising the same for treatment of diseases or conditions (e.g. Parkinson's Disease) in a subject. Also disclosed herein are methods of treating diseases or conditions (e.g. Parkinson's Disease) in a subject by administering engineered latent guide RNAs or pharmaceutical compositions described herein.

Abstract: Described herein are Notch-modulating peptides (including monomers and multimers) capable of increasing or decreasing an immune response in a subject, compositions comprising the peptides, and methods of use thereof.

Abstract: A client device receives a challenge request from a server to prove that internet traffic was initiated by a human user through verifying a physical interaction between a human user and a hardware component. The client device causes a prompt to be displayed to perform the physical interaction with the hardware component. A cryptographic attestation is received that includes an attestation signature that is generated after confirmation that the physical interaction was performed with the hardware component. A zero-knowledge proof of the attestation signature is generated and transmitted to the server for verification. The client device receives the requested content responsive to the server verifying the validity of the zero-knowledge proof.

Abstract: Provided herein are engineered guides configured, upon hybridization to target RNA molecules, to form double stranded RNA substrates comprising (i) a region comprising at least one structural feature; and (ii) a first internal loop and a second internal loop, wherein the double stranded RNA substrates recruit RNA editing entities and facilitate chemical modifications of base nucleotides in the target RNA molecules. Also provided herein are compositions, vectors, and cells comprising the engineered guides disclosed herein. Also provided herein are methods of introducing the engineered guides described herein into cells and methods of treating a disease or condition in a subject in need thereof comprising administering to the subject the engineered guides, polynucleotides encoding the engineered guides, delivery vehicles comprising such engineered guides or such polynucleotides, or pharmaceutical compositions comprising any one of these as described herein.

Abstract: Techniques for generating recommendations for form fields are disclosed. A system obtains user interaction data based on a user's interaction with a digital form. The digital form includes form fields mapped to attribute fields of data object resources. The data object resources specify criteria for when recommendations should be permitted or prohibited for the attribute fields of the business objects. The system obtains the criteria from the data object resources corresponding to the form fields in the digital form. The system compares the user interaction data with the recommendation enablement criteria to determine whether to allow the generation and presentation of recommendations for respective form fields. If the recommendation enablement criteria are met, the system applies a recommendation-type machine learning model to a set of input data including the user interaction data to generate a set of recommendations for a form field.

Abstract: Disclosed herein are engineered guide RNAs and compositions comprising the same for treatment of diseases or conditions in a subject. Also disclosed herein are methods of treating diseases or conditions in a subject by administering engineered guide RNAs or pharmaceutical compositions described herein.

Abstract: Disclosed herein are engineered guide RNAs and compositions comprising the same for treatment of diseases or conditions in a subject. Also disclosed herein are methods of treating diseases or conditions in a subject by administering engineered guide RNAs or pharmaceutical compositions described herein.

Abstract: Methods and compositions are provided for performing an in vivo proximity-ligation in combination with DNA capture technology to cross-link physically adjacent DNA sequences within a mixed population of cells and isolate cross-linked DNA junctions where at least one DNA sequence of interest is present.

Abstract: Techniques for generating application interfaces based on semantic-level data are described herein. Application developers may semantically define an application flow. Based on the definition, a system may identify a template of a multipage navigable interface that is compatible with the flow. If multiple templates are compatible, then a template may be recommended or automatically selected based on the semantic information provided by the developer. The system may generate, based on the template and the semantic definition, a multipage navigable interface. The template may encapsulate some design and functional elements in a manner that is independent of the semantic definition.

Abstract: Methods and compositions are provided for performing an in vivo proximity-ligation in combination with DNA capture technology to cross-link physically adjacent DNA sequences within a mixed population of cells and isolate cross-linked DNA junctions where at least one DNA sequence of interest is present.

Abstract: A corporate credit ratings methodology based on the measurement of overall organisational performance is defined and explained. The overall organisational performance is then further explained that it can be derived by measuring over-arching variables of stability, resilience and sustainability. The overall organisational performance corresponds to existing ratings scale which shows corporate credit ratings can be given from the derived overall organisational performance for each company. The values of sub-dimensions can be collected and benchmarked from public and private data sources as explained in the embodiments. A collected data points can be benchmarked, weighted and finally values of stability, resilience and sustainability can be generated leading to the overall organisational performance score and its further interpretation into assigning a corresponding credit ratings to a corporate.

Abstract: Provided herein are compositions of engineered guide RNAs relating to providing or engineering a structural target to attract adenosine deaminase acting on RNA (ADAR) editing to a desired site and methods of use thereof. Further provided herein are compositions and methods relating to recombinant adenosine deaminase acting on RNA (ADAR) split guide RNAs (adar-sgRNA). In certain embodiments, the adar-sgRNA composition comprises two guides-one guide with an ADAR recruiting domain and a second guide with a 5? and/or 3? RNA targeting domain for forming a trimolecular complex at a mismatch site that serves to recruit ADAR. Binding of the two adar-split gRNAs to the target RNA forms a trimolecular complex which recruits ADAR enzymes to deaminate one or more mismatched adenosine residues in the adar-split gRNA RNA targeting domain: target RNA duplex. In certain embodiments, such compositions and methods will be useful for modifying a coding sequence of a desired protein.

Abstract: A method and devices for making needle insertion safer and easier (NISE). NISE or CISE device includes a small needle, cannula, and large needle in a nested assembly to provide less trauma to a target vessel during large needle insertion. The small needle is movable and within the cannula to a position exterior the cannula. The cannula is movable within the large needle. In a preferred assembly, the cannula is provided with a dulled tip having a beak and successive cutting edges along a tapered shape. The device can be provided in a stand-alone device or alternately integrated into existing off the shelf and currently available vascular devices.

Abstract: Provided herein are compositions and methods relating to providing or engineering a structural target to attract ADAT editing to a desired site. Further provided herein are compositions and methods relating to recombinant adenosine deaminase acting on tRNA (ADAT) guide tRNAs (adat-gtRNA). In certain embodiments, such compositions and methods will be useful for modifying a coding sequence of a desired protein. Also provided are methods of treating a disease or disorder associated with loss of wild-type protein expression.

Abstract: A DNS server receives, from a client device, a DNS query for a resource record type at a domain name. The DNS server determines that the resource record type does not exist at the domain name and generates an answer that indicates that the queried resource record type does not exist at the domain name and also indicates that a plurality of other resource record types exist at the domain name regardless of whether those plurality of other resource record types actually exist at the domain name. The DNS server transmits the generated answer to the client device.

Abstract: A microfluidic delivery device and method of dispensing a fluid composition from a microfluidic die are provided. The method includes generating air flow from a fan; directing a first portion of the air flow through a first air outlet in a housing; directing a second portion of the air flow through a second air outlet in the housing; jetting a fluid composition from a microfluidic die through a fluid orifice in the housing; directing the second portion of air flow adjacent to the microfluidic die and out the fluid outlet, wherein the first portion of the air flow directs the fluid composition jetted out of the fluid outlet into the air.

Abstract: This disclosure relates to methods and exemplary devices for making needle insertion safer and easier (NISE). This NISE device includes at small needle, cannula, and large needle in a nested assembly to provide less trauma to a target vessel during large needle insertion. The small needle is movable relative to a body of the device and within the cannula to a position exterior the cannula. The cannula is movable within the large needle to a position exterior to the large needle. In a preferred assembly, the cannula is provided with a dulled tip and successive cutting edges along a tapered shape from the narrow dulled tip to the cannula body, such that the cannula blunt tip prevents trauma during insertion while the successive cutting edges generally enlarge the opening for placement of the large needle. The device can be provided in a stand alone device or alternately integrated into existing off the shelf and currently available vascular devices.

Abstract: A client device receives a challenge request from a server to prove that internet traffic was initiated by a human user through verifying a physical interaction between a human user and a hardware component. The client device causes a prompt to be displayed to perform the physical interaction with the hardware component. A cryptographic attestation is received that includes an attestation signature that is generated after confirmation that the physical interaction was performed with the hardware component. A zero-knowledge proof of the attestation signature is generated and transmitted to the server for verification. The client device receives the requested content responsive to the server verifying the validity of the zero-knowledge proof.